Keros Therapeutics, Inc. (KROS)
NASDAQ: KROS · Real-Time Price · USD
10.41
+0.38 (3.79%)
At close: Jun 17, 2026, 4:00 PM EDT
10.41
-0.01 (-0.05%)
After-hours: Jun 17, 2026, 4:36 PM EDT
Keros Therapeutics Employees
Keros Therapeutics had 87 employees as of March 31, 2026. The number of employees increased by 9 or 11.54% since the number was last reported on December 31, 2025.
Employees
87
Change
9
Growth
11.54%
Revenue / Employee
$381,402
Profits / Employee
-$978,678
Market Cap
206.03M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Mar 31, 2026 | 87 | 9 | 11.54% |
| Dec 31, 2025 | 78 | -91 | -53.85% |
| Dec 31, 2024 | 169 | 33 | 24.26% |
| Dec 31, 2023 | 136 | 31 | 29.52% |
| Dec 31, 2022 | 105 | 45 | 75.00% |
| Dec 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Karyopharm Therapeutics | 228 |
| LENZ Therapeutics | 152 |
| Arcturus Therapeutics Holdings | 111 |
| Nkarta | 108 |
| Immunic | 95 |
| Compugen | 75 |
| Whitehawk Therapeutics | 29 |
| Unicycive Therapeutics | 22 |
KROS News
- 9 days ago - Keros Therapeutics Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026 - Transcripts
- 16 days ago - Keros Therapeutics Announces Participation at Goldman Sachs 47th Annual Global Healthcare Conference - GlobeNewsWire
- 4 weeks ago - Keros Therapeutics reports Q1 EPS ($1.21), consensus (92c) - TheFly
- 4 weeks ago - Keros Therapeutics Reports Recent First Quarter 2026 Financial Results - GlobeNewsWire
- 4 weeks ago - Keros Therapeutics Earnings release: Q1 2026 - Filings
- 4 weeks ago - Keros Therapeutics Quarterly report: Q1 2026 - Filings
- 2 months ago - Keros Therapeutics Proxy statement: Proxy filing - Filings
- 2 months ago - Keros Therapeutics Proxy statement: Proxy filing - Filings